Review ArticlesMaintenance Strategies for Myeloma Is Bigger Always Better?Nooka, Ajay K. MD, MPH, FACP; Joseph, Nisha S. MD Author Information Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Ajay K. Nooka, MD, MPH, FACP, Department of Hematology and Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, B4120, Atlanta, GA 30322. E-mail: [email protected]. The Cancer Journal: 5/6 2021 - Volume 27 - Issue 3 - p 231-238 doi: 10.1097/PPO.0000000000000524 Buy Metrics Abstract Over the last decade, several very important prospective randomized controlled trials have confirmed the significant survival benefit conferred by maintenance therapies. Owing to these developments, the role of continued maintenance in the optimal management strategies of newly diagnosed myeloma patients (both transplant-eligible and transplant-ineligible) has been strongly cemented. In dealing with an incurable disease such as myeloma, whether to offer maintenance is no longer as relevant a question as it was before, but which antimyeloma agent or agents to use, as maintenance remains more pertinent today. More importantly, a personalized risk-stratified maintenance approach for an individual patient to yield the best benefit for that specific patient is yet to be uniformly adapted. In this article, we review the available and evolving clinical data leading to our current-day practices, and we make an effort to describe what lies ahead. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.